114 related articles for article (PubMed ID: 37094793)
21. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.
Qin Y; Jiang L; Yu M; Li Y; Zhou X; Wang Y; Gong Y; Peng F; Zhu J; Liu Y; Xu Y; Zhou L; Lu Y; Huang M
Sci Rep; 2020 Sep; 10(1):16150. PubMed ID: 32999345
[TBL] [Abstract][Full Text] [Related]
23. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
[TBL] [Abstract][Full Text] [Related]
24. Case Report: A Case Report of a Histological Transformation of
Zhang Y; Qin Y; Xu H; Yao Q; Gao Y; Feng Y; Ren J
Pathol Oncol Res; 2021; 27():637745. PubMed ID: 34257603
[TBL] [Abstract][Full Text] [Related]
25. The mechanism of ABL1 upregulating the expression of PD-L1 and the therapeutic effect of PD-L1 and STAT3 inhibitors in lung adenocarcinoma.
Tang D; Jiang H; Li Z; Gao W; Sun Y
Neoplasma; 2021 May; 68(3):472-481. PubMed ID: 33147049
[TBL] [Abstract][Full Text] [Related]
26. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Cai Y; Wu H; Shi X; Dong Y; Chang X; Zhang L; Zhou L; Su D; Yang M
BMC Cancer; 2020 Feb; 20(1):148. PubMed ID: 32093629
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
[TBL] [Abstract][Full Text] [Related]
29. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
30. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
Dong W; Lei P; Liu X; Li Q; Cheng X
Front Immunol; 2021; 12():686057. PubMed ID: 34804000
[TBL] [Abstract][Full Text] [Related]
31. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
32. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
33. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
34. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
36. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
[TBL] [Abstract][Full Text] [Related]
38. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
Cho JH; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
J Cancer Res Clin Oncol; 2019 May; 145(5):1341-1349. PubMed ID: 30900155
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
40. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
